

Recro Pharma, Inc.  
Form SC 13G  
September 15, 2014  
UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934  
(Amendment No. )

RECRO PHARMA, INC.  
(Name of Issuer)

Common Stock  
(Title of Class of Securities)

75629F109  
(CUSIP Number)

September 5, 2014  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\_\_\_\_\_

The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No 75629F109

1. NAME  
OF  
REPORTING  
PERSONS  
I.R.S.  
IDENTIFICATION  
NOS.  
OF  
ABOVE  
PERSONS  
(ENTITIES  
ONLY)

Broadfin  
Capital,  
LLC

2. CHECK THE  
APPROPRIATE  
BOX IF A  
MEMBER OF A  
GROUP (SEE  
INSTRUCTIONS)  
(a)   
(b)

3. SEC  
USE  
ONLY

4. CITIZENSHIP  
OR  
PLACE  
OF  
ORGANIZATION

Delaware

5. NUMBER OF SHARES  
BENEFICIALLY  
OWNED BY EACH  
REPORTING PERSON  
WITH

SOLE  
VOTING  
POWER

0

6. SHARED  
VOTING  
POWER

1,172,195

7. SOLE  
DISPOSITIVE  
POWER

0

8. SHARED  
DISPOSITIVE  
POWER

1,172,195

9. AGGREGATE  
AMOUNT  
BENEFICIALLY  
OWNED BY EACH  
REPORTING  
PERSON

1,172,195

10. CHECK  
BOX  
IF  
THE  
AGGREGATE  
AMOUNT  
IN  
ROW  
(9)  
EXCLUDES  
CERTAIN  
SHARES  
(SEE  
INSTRUCTIONS)

11. PERCENT  
OF

CLASS  
REPRESENTED  
BY  
AMOUNT  
IN  
ROW  
(9)

15.21%

12. TYPE  
OF  
REPORTING  
PERSON  
(SEE  
INSTRUCTIONS)

OO

---

CUSIP No 75629F109

1. NAME  
OF  
REPORTING  
PERSONS  
I.R.S.  
IDENTIFICATION  
NOS.  
OF  
ABOVE  
PERSONS  
(ENTITIES  
ONLY)

Broadfin  
Healthcare  
Master  
Fund,  
Ltd.

2. CHECK THE  
APPROPRIATE  
BOX IF A  
MEMBER OF A  
GROUP (SEE  
INSTRUCTIONS)  
(a)   
(b)

3. SEC  
USE  
ONLY

4. CITIZENSHIP  
OR  
PLACE  
OF  
ORGANIZATION

Cayman  
Islands

NUMBER OF SHARES  
BENEFICIALLY  
OWNED BY EACH  
REPORTING PERSON  
WITH

5. SOLE  
VOTING  
POWER
- 0
6. SHARED  
VOTING  
POWER
- 1,172,195
7. SOLE  
DISPOSITIVE  
POWER
- 0
8. SHARED  
DISPOSITIVE  
POWER
- 1,172,195
9. AGGREGATE  
AMOUNT  
BENEFICIALLY  
OWNED BY EACH  
REPORTING  
PERSON
- 1,172,195
10. CHECK  
BOX  
IF  
THE  
AGGREGATE  
AMOUNT  
IN  
ROW  
(9)  
EXCLUDES  
CERTAIN  
SHARES  
(SEE  
INSTRUCTIONS)  
[ ]
11. PERCENT  
OF

CLASS  
REPRESENTED  
BY  
AMOUNT  
IN  
ROW  
(9)

15.21%

12. TYPE  
OF  
REPORTING  
PERSON  
(SEE  
INSTRUCTIONS)

CO

---

CUSIP No 75629F109

1. NAME  
OF  
REPORTING  
PERSONS  
I.R.S.  
IDENTIFICATION  
NOS.  
OF  
ABOVE  
PERSONS  
(ENTITIES  
ONLY)

Kevin  
Kotler

2. CHECK THE  
APPROPRIATE  
BOX IF A  
MEMBER OF A  
GROUP (SEE  
INSTRUCTIONS)

(a)   
(b)

3. SEC  
USE  
ONLY

4. CITIZENSHIP  
OR  
PLACE  
OF  
ORGANIZATION

United  
States  
of  
America

- NUMBER OF SHARES  
BENEFICIALLY OWNED BY  
EACH REPORTING PERSON  
WITH

- 5.



- SOLE  
VOTING  
POWER
- 0
6. SHARED  
VOTING  
POWER
- 1,172,195
7. SOLE  
DISPOSITIVE  
POWER
- 0
8. SHARED  
DISPOSITIVE  
POWER
- 1,172,195
9. AGGREGATE  
AMOUNT  
BENEFICIALLY  
OWNED BY EACH  
REPORTING  
PERSON
- 1,172,195
10. CHECK  
BOX  
IF  
THE  
AGGREGATE  
AMOUNT  
IN  
ROW  
(9)  
EXCLUDES  
CERTAIN  
SHARES  
(SEE  
INSTRUCTIONS)  
[ ]
11. PERCENT  
OF

CLASS  
REPRESENTED  
BY  
AMOUNT  
IN  
ROW  
(9)

15.21%

12.

TYPE  
OF  
REPORTING  
PERSON  
(SEE  
INSTRUCTIONS)

IN,  
HC

---

CUSIP  
No 75629F109

Item 1. (a) Name of  
Issuer:

Recro  
Pharma, Inc.

Address of  
Issuer's

(b) Principal  
Executive  
Offices:

490 Lapp  
Road,  
Malvern,  
Pennsylvania  
19355 United  
States of  
America

Item 2. (a) Name of  
Person Filing:

Broadfin  
Capital, LLC  
Broadfin  
Healthcare  
Master Fund,  
Ltd.  
Kevin Kotler

Address of  
Principal

(b) Business  
Office, or if  
None,  
Residence:

Broadfin  
Capital, LLC  
237 Park  
Avenue, Suite  
900  
New York,  
New York

10017  
United States  
of America

Broadfin  
Healthcare  
Master Fund,  
Ltd.  
20 Genesis  
Close  
Ansbacher  
House,  
Second Floor  
P.O. Box  
1344  
Grand  
Cayman  
KY1-1108  
Cayman  
Islands

Kevin Kotler  
c/o Broadfin  
Capital, LLC  
237 Park  
Avenue, Suite  
900  
New York,  
New York  
10017  
United States  
of America

(c) Citizenship:

Broadfin  
Capital, LLC –  
Delaware  
Broadfin  
Healthcare  
Master Fund,  
Ltd. – Cayman  
Islands  
Kevin Kotler –  
United States  
of America

(d) Title of Class  
of Securities:

Common  
Stock

(e) CUSIP  
Number:

75629F109

---

Edgar Filing: Recro Pharma, Inc. - Form SC 13G

Item 3. If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

- (a)  Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
- (b)  Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
- (c)  Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
- (d)  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
- (e)  An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f)  An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g)  A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- (h)  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
- (i)  A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j)  Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

Broadfin Capital, LLC – 1,172,195  
Broadfin Healthcare Master Fund, Ltd. –  
1,172,195  
Kevin Kotler – 1,172,195

(b) Percent of class:

Broadfin Capital, LLC – 15.21%  
Broadfin Healthcare Master Fund, Ltd. –  
15.21%  
Kevin Kotler – 15.21%

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote

Broadfin Capital, LLC – 0

Broadfin Healthcare Master Fund, Ltd. – 0

Kevin Kotler – 0

---

(ii) Shared power to vote or to direct the vote

Broadfin Capital, LLC – 1,172,195  
Broadfin Healthcare Master Fund, Ltd. – 1,172,195  
Kevin Kotler – 1,172,195

(iii) Sole power to dispose or to direct the disposition of

Broadfin Capital, LLC – 0  
Broadfin Healthcare Master Fund, Ltd. – 0  
Kevin Kotler – 0

(iv) Shared power to dispose or to direct the disposition of

Broadfin Capital, LLC – 1,172,195  
Broadfin Healthcare Master Fund, Ltd. – 1,172,195  
Kevin Kotler – 1,172,195

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

N/A

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

N/A





Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

N/A

Item 9. Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

N/A

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

---

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

September 15, 2014  
(Date)

BROADFIN CAPITAL, LLC\*  
By: /s/ Kevin Kotler  
(Signature)

Kevin Kotler, Managing Member  
(Name/Title)

September 15, 2014  
(Date)

BROADFIN HEALTHCARE  
MASTER FUND, LTD.  
By: /s/ Kevin Kotler  
(Signature)

Kevin Kotler, Director  
(Name/Title)

September 15, 2014  
(Date)

By: /s/ Kevin Kotler\*  
(Signature)

Kevin Kotler  
(Name/Title)

\*The Reporting Persons disclaim beneficial ownership in the shares reported herein except to the extent of their pecuniary interest therein.

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an

Edgar Filing: Recro Pharma, Inc. - Form SC 13G

executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

---

AGREEMENT

The undersigned agree that this Schedule 13G dated September 15, 2014 relating to the Common Stock, \$0.01 par value per share, of Recro Pharma, Inc. shall be filed on behalf of the undersigned.

September 15, 2014  
(Date)

BROADFIN CAPITAL, LLC  
By: /s/ Kevin Kotler  
(Signature)

Kevin Kotler, Managing Member  
(Name/Title)

September 15, 2014  
(Date)

BROADFIN HEALTHCARE  
MASTER FUND, LTD.  
By: /s/ Kevin Kotler  
(Signature)

Kevin Kotler, Director  
(Name/Title)

September 15, 2014  
(Date)

By: /s/ Kevin Kotler  
(Signature)

Kevin Kotler  
(Name/Title)

The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

Edgar Filing: Recro Pharma, Inc. - Form SC 13G

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).